Lung Cancer, Nonsmall Cell, Stage I Withdrawn Phase 2 Trials for Nivolumab (DB09035)

Also known as: NSCLC, Stage I / Stage I NSCLC / Stage I Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer Stage I / Lung cancer non-small cell stage I

DBCOND0081601 (Lung Cancer, Nonsmall Cell, Stage I)Withdrawn2 IdentifierTitlePurposeDrugs
NCT02950038Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)Treatment